RXRX (Recursion Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

RXRX (Recursion Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$75M

Net Income (TTM)-$645M

EPS (TTM)-$1.48

Free Cash Flow (TTM)-$378M

Gross Margin-32.1%

Op. Margin-869.3%

Net Margin-864.7%

FCF Margin-507.3%

P/S Ratio (TTM)21.1x

P/E Ratio (TTM)—

YoY Rev Growth+27.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$12M	-$314K	-$70M
Q2 23	$11M	$2M	-$82M
Q3 23	$10M	-$775K	-$100M
Q4 23	$11M	$743K	-$99M
Q1 24	$13M	$2M	-$96M
Q2 24	$14M	$5M	-$101M
Q3 24	$26M	$14M	-$98M
Q4 24	$5M	-$8M	-$184M
Q1 25	$15M	-$7M	-$191M
Q2 25	$19M	-$1M	-$176M
Q3 25	$5M	-$24M	-$172M
Q4 25	$36M	$9M	-$108M

Valuation

Quarter	P/S	P/E
Q1 23	33.8x	—
Q2 23	31.6x	—
Q3 23	33.5x	—
Q4 23	35.9x	—
Q1 24	34.8x	—
Q2 24	32.4x	—
Q3 24	24.4x	—
Q4 24	26.9x	—
Q1 25	26.3x	—
Q2 25	24.4x	—
Q3 25	36.2x	—
Q4 25	21.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$73M	-$79M
Q2 23	-$67M	-$71M
Q3 23	-$73M	-$74M
Q4 23	-$74M	-$76M
Q1 24	-$102M	-$109M
Q2 24	-$82M	-$86M
Q3 24	-$59M	-$64M
Q4 24	-$115M	-$117M
Q1 25	-$132M	-$134M
Q2 25	-$76M	-$80M
Q3 25	-$117M	-$118M
Q4 25	-$46M	-$47M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$5M
Q2 23	$4M
Q3 23	$827K
Q4 23	$2M
Q1 24	$7M
Q2 24	$4M
Q3 24	$5M
Q4 24	$2M
Q1 25	$2M
Q2 25	$3M
Q3 25	$243K
Q4 25	$1M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+129.0%	+33.8%
Q2 23	+43.9%	+25.6%
Q3 23	-22.6%	+45.0%
Q4 23	-22.3%	+46.7%
Q1 24	+11.2%	+33.9%
Q2 24	+30.8%	+24.0%
Q3 24	+158.2%	+13.5%
Q4 24	-57.5%	+71.9%
Q1 25	+9.3%	+87.7%
Q2 25	+32.6%	+69.9%
Q3 25	-80.2%	+42.5%
Q4 25	+687.8%	-23.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$9M	72.6%
Q2 23	$12M	107.2%
Q3 23	$17M	166.2%
Q4 23	$16M	151.4%
Q1 24	$16M	119.5%
Q2 24	$17M	114.7%
Q3 24	$18M	70.0%
Q4 24	$31M	682.4%
Q1 25	$36M	244.5%
Q2 25	$26M	136.9%
Q3 25	$25M	487.8%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$47M	$23M
Q2 23	$55M	$28M
Q3 23	$70M	$29M
Q4 23	$69M	$30M
Q1 24	$68M	$31M
Q2 24	$74M	$32M
Q3 24	$75M	$38M
Q4 24	$98M	$77M
Q1 25	$130M	$55M
Q2 25	$129M	$47M
Q3 25	$121M	$42M
Q4 25	$83M	$34M

Revenue Segments

Quarter	License and Service	Grant
Q1 23	$12M	—
Q2 23	$11M	$1K
Q3 23	$10M	$431K
Q4 23	$11M	$267K
Q1 24	$13M	$303K
Q2 24	$14M	$13K
Q3 24	$26M	—
Q1 25	$15M	—
Q2 25	$19M	$120K
Q3 25	$5M	$192K
Q4 25	$35M	$186K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$473M	$0	$473M
Q2 23	$406M	$0	$406M
Q3 23	$387M	$0	$387M
Q4 23	$392M	$0	$392M
Q1 24	$300M	$0	$300M
Q2 24	$474M	$0	$474M
Q3 24	$428M	$0	$428M
Q4 24	$594M	$0	$594M
Q1 25	$500M	$0	$500M
Q2 25	$528M	$0	$528M
Q3 25	$660M	$0	$660M
Q4 25	$743M	$0	$743M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	192M	+3.2%
Q2 23	201M	+5.1%
Q3 23	214M	+6.4%
Q4 23	233M	+8.8%
Q1 24	236M	+1.2%
Q2 24	242M	+2.6%
Q3 24	283M	+16.7%
Q4 24	336M	+18.9%
Q1 25	403M	+19.9%
Q2 25	417M	+3.6%
Q3 25	447M	+7.1%
Q4 25	527M	+17.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$25K	400
FY 22	$79K	500
FY 23	$88K	500
FY 24	$74K	800
FY 25	$373	200K